European Brain Council declares 2014 the ‘Year of The Brain1In total, disorders of the brain costs the UK around £112 billion a year2 The annual cost, to the UK, of Epilepsy, Parkinson’s Disease and Sleep Disorders is approximately £8.2 billion2 As one of the UK’s leading R&D pharmaceutical investors with a focus on the central nervous system and the immune system we are committed to discovering new treatments for brain related disorders
Slough, UK, 4 February 2014: The European Brain Council pledged to make 2014 the European Year of the Brain and as a science skills leader with a strong heritage in providing medicines for conditions of the central nervous system, UCB supports this initiative. During the ‘Year of the Brain’ in Europe, UCB will raise awareness, educate, and challenge current perceptions around brain-related illnesses.
Did you know - that there are over 600 neurological diseases affecting the brain3
Epilepsy is the most common, serious brain disorder worldwide.4 More than half a million people in the UK have epilepsy, which is about 1 in 100 people5. Epilepsy is most commonly diagnosed in children and people aged 65 and over but can affect anyone regardless of race and social classes.5 It is reported that there are approximately 32,000 new cases of epilepsy in the UK each year.6 Epilepsy is not a single condition, and doctors have described more than 40 different types of seizure that may affect people living with epielpsy.5 While 70% of people with epilepsy could obtain freedom from their seizures with optimal drug treatments, that leaves 30% of people living with epilepsy who do not respond adequately to current drug treatments.6,7
Did you know - the human brain is made up of 100 billion nerve cells and each cell is connected to around 10,000 other cells8
Parkinson’s Disease affects an estimated 127,000 people in the UK9. Parkinson’s is more prevalent in adults over the age of 50 however it can occur in younger people with recent figures highlighting that 1 in 20 Parkinson’s patients in the UK are under the age of 40.9 Parkinson’s can be disabling with symptoms progressing with age and impairing cognitive function.10 There is a whole spectrum of symptoms that can severely impact upon a patient’s quality of life such as tremors, rigidity, slowness of movement, pain, depression, constipation, difficulty in swallowing and sleep disturbance, as well as many more11. There is no cure for Parkinson’s but there are a number of available treatments which help to alleviate symptoms12.
Did you know - up to 4,000 new nerve cells are made by the brain every second8
Restless Leg Syndrome (RLS) is a chronic neurological disorder described as an urge to move the legs, especially at rest.13, 14 Symptoms are mainly felt in the legs and can include: a crawling sensation, feeling like water running down the leg as well as deep pain within the leg.15 In many cases of RLS, the exact cause is unknown. Some doctors think that symptoms may have something to do with how the body handles a chemical in the brain called dopamine.14 Some cases of RLS may be caused by underlying health conditions such as iron deficiency or kidney failure.14 An estimated 1 in 10 people will develop RLS at some point in their lives and it tends to affect women more than men and can occur at any point in life.15 RLS can be disruptive to sleep that may impact upon cognition16,17. In a survey, 28% of adults reported that they had missed work due to impact upon sleep.17 There is currently no cure for RLS but therapeutic options are available to help reduce symptoms.18
Did you know - every experience you have will impact on the structure of your brain19
Narcolepsy is a rare but serious brain disorder. It can cause a person to fall asleep suddenly without warning and at any time. Symptoms include sleep attacks, excessive daytime sleepiness, and temporary muscle weakness as a response to emotions such as laughter and anger – known as cataplexy20. It is difficult to quantify exactly how many people have narcolepsy but it is estimated that at least 25,000 people in the UK are affected by the condition20. Narcolepsy affects both men and women equally. There is currently no cure for narcolepsy however there are a number of medications and behavioural techniques that doctors or sleep specialists can use to manage the condition21.
For further information
Scott Fleming, Head of Communications, British Irish Isles, UCBT +44 7702777378, email@example.com
Erin Hamid, Brand Communications Manager, British Irish Isles, UCBT +44 7921 046 443, firstname.lastname@example.org
1. European Brain Council accessed January 2014 from http://www.europeanbraincouncil.org/projects/eyob/ 2. Wong, S. 2013. Cost of brain disorders to the UK estimated at £112 billion a year accessed January 2014 from http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_24-7-2013-16-9-13 3. National Institute of Health. A service of the U.S. National Library of Medicine. Accessed January 2014 from http://www.nlm.nih.gov/medlineplus/neurologicdiseases.html4. World Health Organization. Neurological disorders, including epilepsy. Accessed January 2014 from http://www.who.int/mental_health/management/neurological/en/ 5. Epilepsy Society. What is Epilepsy? Accessed January 2014 from http://www.epilepsysociety.org.uk/AboutEpilepsy/Whatisepilepsy 6. Deacon K, Wigglesworth S. Epilepsy, prevalence, incidence and other statistics. Joint Epilepsy Council of the UK and Ireland; 20117. Epilepsy Society. Treatment. Accessed January 2014 from http://www.epilepsysociety.org.uk/treatment#.UulJy_uF98E8. Sciencemuseum.org.uk. Who am I? Accessed January 2014 from http://www.sciencemuseum.org.uk/whoami/findoutmore/yourbrain/howdoesyourbrainwork.aspx 9. Parkinson’s.org.uk. What is Parkinson’s? Parkinson’s UK Accessed January 2014 from http://www.parkinsons.org.uk/content/what-parkinsons 10. Grosset D G et al. Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines. BMJ 2010; 340:b5614: 1-1011. Parkinsons.org.uk. Parkinson’s Symptoms accessed January 2014 from http://www.parkinsons.org.uk/content/parkinsons-symptoms12. Parkinsons.org.uk. Treatments and therapies for Parkinson’s. Accessed January 2014 from http://www.parkinsons.org.uk/content/treatments-and-therapies-parkinsons13. Garcia-Borreguero et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care (EURLSSG Guidelines).BMC Neurology 2011, 11-2814. Restless Leg Syndrome. Accessed January 2014 from NHS Choices http://www.nhs.uk/Conditions/Restless-leg-syndrome/Pages/Symptoms.aspx15. Patient.co.uk. Restless Legs Syndrome. Accessed January 2014 from www.patient.co.uk/health/Restless-Legs-Syndrome.htm16. RLS-UK.org Welcome to RLS-UK accessed January 2014 from http://www.rls-uk.org/17. National Sleep Foundation. Sleep related problems. RLS and Sleep. Accessed January 2014 from http://www.sleepfoundation.org/article/sleep-related-problems/restless-legs-syndrome-rls-and-sleep18. NHS Choices. Restless Legs Syndrome – Treatment. Accessed January 2014 from http://www.nhs.uk/Conditions/Restless-leg-syndrome/Pages/Treatment.aspx 19. Science Museum. How changeable is your brain? Accessed January 2014 from http://www.sciencemuseum.org.uk/WhoAmI/FindOutMore/Yourbrain/Howdoesyourbraingrow/Howchangeableisyourbrain.aspx 20. NHS Choices. Narcolepsy. Introduction. Accessed January 2014 from http://www.nhs.uk/Conditions/b Narcolepsy/Pages/Introduction.aspx 21. NHS Choices. Narcolepsy – Treatment. Accessed January 2014 from http://www.nhs.uk/Conditions/Narcolepsy/Pages/Treatment.aspx
About UCBUCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
Forward looking statementsThis press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
All media outlets - Feb 2014 - UK/14MIS0005
© 2011 -